Elanco Animal Health Inc 4

Elanco Animal Health CEO Jeffrey N. Simmons received an award of 113.8973 deferred stock units convertible into common stock, a routine compensation-related grant of roughly $2,830 in value.

On July 10, 2026, Elanco Animal Health Inc. President, CEO and Director Jeffrey N. Simmons received 113.8973 deferred stock units at an implied value of approximately $24.82 per unit (about $2,830 in total), credited under the company’s Executive Deferral and Stock Match Plan. Each deferred stock unit represents a right to receive either one share of Elanco common stock or the cash equivalent, generally following termination of employment or in a specified future year, and is reflected as a derivative award converting into common stock. Following this routine compensation-related award, Simmons’ directly held common stock position is reported at 24,770.9021 shares, worth roughly $632,000 based on the recent market price of about $25.55 per share, in addition to the newly credited deferred stock units that will settle in the future.

Filing Facts

CIK

1739104

Ticker

ELAN

Form

4

Source Type

fda

Accession

0001479079-26-000033

Alert Tier

4